In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gilead steps up to buy CV Therapeutics for $20 per share

Executive Summary

Gilead has emerged as the white knight for CV Therapeutics, offering $20 per share (valuing the deal at about $1.28bn) for the public cardiovascular company just weeks after Astellas launched a hostile bid of $16 per share. The price per share amounts to an 87% premium based on the ten-day average of CV's shares prior to the announcement of Astellas's offer. CV's board of directors immediately and unanimously approved Gilead's offer, and recommended that shareholders do the same.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies